COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT
The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.
The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.
MEMBERS OF THE BOARD:
 |
 |
 |
 |
| Ken Newport Chair, Board of Directors |
Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa |
Dr. Josée Brisebois Executive consultant in the biopharma and health sciences sectors |
Karimah Es Sabar Chief Executive Officer & Partner, Quark Venture LP |
 |
 |
 |
 |
| Dr. David Poon Chief Business Officer, Gandeeva |
Doreen Hume Partner, Audit & Assurance, Deloitte Canada |
Dr. John Stagg Associate Professor, Faculty of Pharmacy at the University of Montreal Lab Head at the CHUM Hospital Research Centre |
Antonia Palmer Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network |
 |
|||
| Russell Williams Senior Vice President, Mission, Diabetes Canada |
EX-OFFICIO MEMBERS (NON-VOTING)
 |
| Dr. Stéphanie Michaud President and CEO, BioCanRx Secretary, Board of Directors |
OBSERVERS
 |
|||
| Sara Esam Senior Program Manager, College and Networks, Networks of Centres of Excellence (NCE) |
